Cargando…

Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis

In our clinical experience, more than half of patients do not present a complete response to biologic drugs, or drug loses its efficacy over time. Plasma determinations of drug and anti-drug antibodies levels are an objective tool for optimisation in these patients; however, established therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dodero-Anillo, Jose Manuel, Lozano-Cuadra, Inmaculada Concepcion, Rios-Sanchez, Esmeralda, Pedrosa-Martinez, Maria Jose, Ruiz-Carrascosa, Jose Carlos, Galan-Gutierrez, Manuel, Armario-Hita, Jose Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787329/ https://www.ncbi.nlm.nih.gov/pubmed/36556440 http://dx.doi.org/10.3390/life12122075

Ejemplares similares

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis
por: Pereyra-Rodriguez, José-Juan, et al.
Publicado: (2021)

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis
por: Zozaya, Néboa, et al.
Publicado: (2018)

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning
por: Alcantara-Luna, Sara, et al.
Publicado: (2022)

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
por: Vidal, Silvia, et al.
Publicado: (2021)

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review
por: Ayen-Rodríguez, Angela, et al.
Publicado: (2022)

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740
por: Vidal, Silvia, et al.
Publicado: (2022)

104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()()
por: Pereyra-Rodriguez, Jose Juan, et al.
Publicado: (2021)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy
por: Ricardo, Ruiz-Villaverde, et al.
Publicado: (2022)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis
por: Molina-Leyva, Alejandro, et al.
Publicado: (2015)

Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document
por: Belinchón Romero, Isabel, et al.
Publicado: (2021)

Four years stability of type D personality in patients with moderate to severe psoriasis and its implications for psychological impairment()()
por: Aguayo-Carreras, Paula, et al.
Publicado: (2021)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient
por: Vinaixa Aranzazu, Arrieta, et al.
Publicado: (2021)

Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment
por: Rivera-Díaz, Raquel, et al.
Publicado: (2023)

Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
por: Kokolakis, Georgios, et al.
Publicado: (2022)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review
por: Belinchon Romero, Isabel, et al.
Publicado: (2023)

Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
por: ZOZAYA, Néboa, et al.
Publicado: (2022)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
por: Smith, Saxon D., et al.
Publicado: (2023)

Block-Based Development of Mobile Learning Experiences for the Internet of Things
por: Ruiz-Rube, Iván, et al.
Publicado: (2019)

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
por: Maravilla-Herrera, Paulina, et al.
Publicado: (2023)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Special Issue “Optimising Interval Training Prescription”
por: Billaut, François
Publicado: (2022)

Modeling Quantum Dot Systems as Random Geometric Graphs with Probability Amplitude-Based Weighted Links
por: Cuadra, Lucas, et al.
Publicado: (2021)

Approaching Disordered Quantum Dot Systems by Complex Networks with Spatial and Physical-Based Constraints
por: Cuadra, Lucas, et al.
Publicado: (2021)

An Overview of REBA Method Applications in the World
por: Hita-Gutiérrez, Manuel, et al.
Publicado: (2020)

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
por: Herranz-Pinto, Pedro, et al.
Publicado: (2023)

Gut microbial composition in patients with psoriasis
por: Codoñer, Francisco M., et al.
Publicado: (2018)

Motivation, students’ needs and learning outcomes: a hybrid game-based app for enhanced language learning
por: Berns, Anke, et al.
Publicado: (2016)

Optimising pre‐operative imaging–surgery intervals for stones
por: Chibuzo, Ijeoma, et al.
Publicado: (2023)

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies
por: Griss, Johannes, et al.
Publicado: (2023)

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
por: Sastre, Joaquín, et al.
Publicado: (2020)

Artificial gametes from stem cells
por: Moreno, Inmaculada, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rvbkj0c46qih8sm517okd9kane